Kerry Wentworth

Chief Regulatory Officer of Flexion Therapeutics

About Kerry

Ms. Wentworth has 25 years of experience in both domestic and international Regulatory Affairs that spans early and late development across multiple therapeutic areas. Ms. Wentworth joined Flexion Therapeutics in 2014 where she’s been responsible for leading the company’s first NDA successfully through the FDA approval process. Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory and Quality at Agenus, Inc., where she was responsible for leading all global regulatory and clinical development efforts for 10 years. Previously, Ms. Wentworth led the Regulatory and Quality function for Genelabs Technologies, Inc. and prior to that held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a BS in pre-veterinary medicine from the University of New Hampshire.

See all Board Members